These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
28. [Homologous recombination deficiency and PARP inhibitors in therapeutics]. Salaün H; Saint-Ghislain M; Bellesoeur A; Beuzeboc P; Neuzillet C; Diéras V; Stern MH; Rodrigues M Bull Cancer; 2022 Jan; 109(1):76-82. PubMed ID: 34799081 [TBL] [Abstract][Full Text] [Related]
29. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
30. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393 [TBL] [Abstract][Full Text] [Related]
31. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. Gadducci A; Guerrieri ME Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105 [TBL] [Abstract][Full Text] [Related]
32. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations. Miller RE; Ledermann JA Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289 [TBL] [Abstract][Full Text] [Related]
33. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. Antonarakis ES; Gomella LG; Petrylak DP Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685 [TBL] [Abstract][Full Text] [Related]
34. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
35. PARP Inhibitors for Cancer Therapy. Lin KY; Kraus WL Cell; 2017 Apr; 169(2):183. PubMed ID: 28388401 [TBL] [Abstract][Full Text] [Related]
36. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112 [TBL] [Abstract][Full Text] [Related]
37. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088 [TBL] [Abstract][Full Text] [Related]
38. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893 [TBL] [Abstract][Full Text] [Related]
39. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K; J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631 [TBL] [Abstract][Full Text] [Related]
40. How safe is rucaparib in ovarian cancer? Cosgrove CM; O'Malley DM Expert Opin Drug Saf; 2018 Dec; 17(12):1249-1255. PubMed ID: 30449210 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]